Evidence map›Paper›PMID 32322463›Full record

ReviewActa pharmaceutica Sinica. B2020

Targeting autophagy-related protein kinases for potential therapeutic purpose.

Honggang Xiang, Jifa Zhang, Congcong Lin, Lan Zhang, Bo Liu, Liang Ouyang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Programmed cell death in triple-negative breast cancer.Cellular & molecular biology letters · 2025
    Review

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Honggang XiangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu 610041, China.
Jifa ZhangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu 610041, China.
Congcong LinState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu 610041, China.
Lan ZhangSchool of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
Bo LiuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu 610041, China.
Liang OuyangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu 610041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autophagy, defined as a scavenging process of protein aggregates and damaged organelles mediated by lysosomes, plays a significant role in the quality control of macromolecules and organelles. Since protein kinases are integral to the autophagy process, it is critically important to understand the role of kinases in autophagic regulation. At present, intervention of autophagic processes by small-molecule modulators targeting specific kinases has becoming a reasonable and prevalent strategy for treating several varieties of human disease, especially cancer. In this review, we describe the role of some autophagy-related kinase targets and kinase-mediated phosphorylation mechanisms in autophagy regulation. We also summarize the small-molecule kinase inhibitors/activators of these targets, highlighting the opportunities of these new therapeutic agents.

Indexed as

4E-BP1, eukaryotic translation initiation factor 4E-binding proteinAKT1, AKT serine/threonine kinase 1AMBRA1, autophagy/beclin-1 regulator 1AMPK, AMP-activated protein kinaseARF, auxin response factor geneATG, autophagy-related proteinAutophagyAutophagy-related kinaseCaMKK2, calcium/calmodulin-dependent protein kinase kinase 2DAPK, death associated protein kinaseFIP200, FAK family kinase-interacting protein of 200 kDaGAP, GTPase-activating proteinGO, gene ontologyGSK3α, glycogen synthase kinase 3 alphaHMGB1, high mobility group protein B1Human disease therapyJNK1, C-Jun N-terminal kinaseLC3, microtubule-associated protein 1 light chain 3LKB1, serine/threonine-protein kinase stk11LPS, lipopolysaccharideLRRK2, leucine rich repeat kinase 2mTORC1, mammalian target of rapamycin complex 1mTOR, mammalian target of rapamycinPD, Parkinson's diseasePhosphorylationPI3 kinase, phosphoinositide 3-kinasePI3P, phosphatidylinositol triphosphatePIM2, proviral insertion in murine lymphomas 2PINK1, PTEN-induced putative kinase 1PIP2, phosphatidylinositol-4,5-bisphosphatePI, phosphatidylinositolPKACα, a protein kinase cAMP-activated catalytic subunit alphaPKCα, protein kinase C alpha typePKD1, polycystin-1PPIs, protein–protein interactionsPROTAC, proteolysis targeting chimerasProtein kinasesPTMs, post-translational modificationsRheb, the RAS homolog enriched in brainSmall-molecule kinase inhibitors/activatorsTAK1, transforming growth factor activated kinase-1TFEB, transcription factor EBTNBC, triple-negative breast cancerTSC1/2, tuberous sclerosis complex proteins 1/2ULK1, unc-51-like kinase 1ULK complex, ULK1–mATG13–FIP200–ATG101 complexUVRAG, ultraviolet resistance-associated gene

Identifiers

PMID32322463
PMCPMC7161711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.